AlphaTON Capital Corp.
ATON • Biotechnology
$0.29
— 0.00 (0.00%)
EarningsLatest report: Mar 31, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$4.78M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.02Weak liquidity · 0.31Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: Mar 31, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:48 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.29
Change0.00%
Shares Out16.32M
Market Cap$4.78M
Enterprise Value$2.98M
52W Range0.18 - 13.80
Beta0.49
P/E-0.11
P/S49.24
P/B0.66
P/FCF-0.13
EV/Sales30.71
Price$0.29
Change0.00%
Shares Out16.32M
Market Cap$4.78M
Enterprise Value$2.98M
52W Range0.18 - 13.80
Beta0.49
P/E-0.11
P/S49.24
P/B0.66
P/FCF-0.13
EV/Sales30.71
EV/EBITDA-0.09
EV/FCF-0.08
Earnings Yield-909.08%
FCF Yield-790.32%
Dividend Yield0.00%
Gross Margin100.00%
Oper. Margin-238.10%
Profit Margin-398.21%
Debt/Eq0.02
Current Ratio0.31
Quick Ratio0.31
Target$4.88
Target Upside1567.81%
Target Median$4.88
Target Range4.50 - 5.25
Volume13.97M
Avg Volume5.24M
EPS Surprise-3.78
Investment DNA
How strong this company looks for long-term investors
36
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
39/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
58/100
Why this score▼
Manageable debt level · 0.02Weak liquidity · 0.31Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 4 analyst votes · 2026-09-04
100/100
Bullish
Bullish
4
Hold
0
Bearish
0
Price Target
2026-08-07
Low
$4.50
Mean
$4.88
Median
$4.88
High
$5.25
🧾
No insider activity
No recent insider transactions available.